Sun Pharma Enters Into A Collaboration With Zydus To Co-Market A Drug Designed To Treat Anemia Induced By Chronic Kidney Disease

Published: November 2023

On 31 October 2023, Zydus Lifesciences and Sun Pharmaceutical Industries entered into a licensing arrangement to jointly commercialize Desidustat, an oral remedy for anemia linked with chronic kidney disease (CKD). This collaborative agreement aims to co-market the product developed by Zydus Lifesciences. In the Indian market, Desidustat serves as an oral remedy for CKD-related anemia.

Sun Pharma is expected to market this medication under the brand name RYTSTAT, while Zydus has been marketing it as Oxemia since 2022 and will continue to do so. Zydus is eligible to receive an upfront licensing fee and also become eligible for milestone payments upon the accomplishment of predefined milestones.

According to Roots Analysis, the Chronic Kidney Diseases Market is estimated to be worth $2.9 billion in 2023 and is expected to grow at a CAGR of 15.1% during the forecast period.

For detailed insights about this domain, check out our report on Chronic Kidney Diseases Market or email

You may also be interested in the following titles: 

  1. Rare Kidney Disease Market, 2022-2035
  2. Human Microbiome Market, 2022-2035
  3. Alzheimer’s Disease Market, 2021-2035


  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry